Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzalutamide in progressive metastatic castration-resistant prostate cancer after abiraterone
2013-002271-17Phase 4Completed
- Sponsor
- Astellas Pharma
- Start
- Feb 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of enzalutamide in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Astellas Pharma. Primary endpoint: Radiographic progression-free survival. Started Feb 2014; status: completed.
02
Drugs
enzalutamide
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2013-002271-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002271-17.